DESTINEE JONES: Open Payments
NPI 1063032704 · SHEFFIELD, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,658 in 123 payments from 10 companies in 2025. Trend: 2023 $222 · 2024 $2,216 · 2025 $2,658
Food & beverage: $2,658
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $874 |
| Madrigal Pharmaceuticals | 15 | $340 |
| Regeneron Healthcare Solutions, Inc. | 10 | $329 |
| Ardelyx, Inc. | 12 | $250 |
| Phathom Pharmaceuticals, Inc. | 14 | $248 |
| Janssen Biotech, Inc. | 10 | $180 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 16 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $141 |
| Lilly USA, LLC | 1 | $111 |
| Gilead Sciences, Inc. | 1 | $28 |
Products named: REZDIFFRA, DUPIXENT, IBSRELA, VOQUEZNA, SKYRIZI, RINVOQ, TREMFYA, ENTYVIO.
Industry payments across AL — which companies pay providers there.
